OmniaBio Inc.: federal grants and contributions: 4 agreements; $39.9M value; 4 departments; 3 programs.
Assay record ASY-CA-1DNAAL215D · Cite as: Assay Systems, “OmniaBio Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/omniabio-inc/
This project will establish automated good manufacturing practice (GMP) facilities in Ontario to produce cell and gene therapy (CGT) products by integrating advanced robotics infrastructure and bioprocessing platforms supported by artificial intelligence.
To scale its domestic cell and gene therapy (CGT) production capabilities by upgrading cleanroom infrastucture, integrating advanced automation, and enhancing digital manufacturing and quality-control systems.
Three CAR-T Analytics Platforms to Support Production: 1. Development & Optimization of Flow Cytometry Panels for CD19 CAR-T Immunophenotyping 2. Development of a qPCR method for CD19 CAR Gene Expression and Vector Copy Number (VCN) 3. Use of Synthetic Cell Mimics for Tech Transfer of Flow Cytometry Panels from Clients to AD/QC teams at OmniaBio
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
All grants from Innovation, Science and Economic Development Canada
All grants from Federal Economic Development Agency for Southern Ontario
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.